MarketCap
Facebook
X
TelegramQuarterly report 2025-Q1
added 05-13-2025
Checkpoint Therapeutics Total Assets 2011-2026 | CKPT
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Checkpoint Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.47 M | 5.38 M | 13.3 M | 55.7 M | 42.6 M | 27 M | 24.9 M | 21.4 M | 36 M | 50.7 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 55.7 M | 5.38 M | 28.4 M |
Quarterly Total Assets Checkpoint Therapeutics
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 34.2 M | 7.47 M | 5.18 M | 5.67 M | - | 5.38 M | 2.22 M | 8.34 M | 5.9 M | 13.3 M | 21.6 M | 32.1 M | 42.9 M | 55.7 M | 61 M | 66.1 M | 61.4 M | 42.6 M | 42.6 M | 42.6 M | 42.6 M | 27 M | 27 M | 27 M | 27 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | 21.4 M | 21.4 M | 21.4 M | 21.4 M | 36 M | 36 M | 36 M | 36 M | 50.7 M | 50.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 66.1 M | 2.22 M | 29.9 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
180 M | - | - | $ 86.2 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
1.19 B | $ 22.56 | 2.13 % | $ 3.74 B | USA |
 |
AlloVir
ALVR
|
122 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
54.8 M | - | - | $ 8.42 M | USA |
 |
Akebia Therapeutics
AKBA
|
377 M | $ 1.43 | 3.62 % | $ 368 M | USA |
 |
argenx SE
ARGX
|
8.68 B | $ 785.07 | 2.57 % | $ 25 B |  Niderland |
 |
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
151 M | - | 2.54 % | $ 160 B |  France |
 |
Alnylam Pharmaceuticals
ALNY
|
4.97 B | $ 327.25 | 2.42 % | $ 42.9 B | USA |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M | France |
 |
Aytu BioScience
AYTU
|
124 M | $ 2.66 | 3.5 % | $ 16.7 M | USA |
 |
AVROBIO
AVRO
|
101 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
114 B | - | - | $ 96.9 B |  Britain |
 |
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
BeiGene, Ltd.
BGNE
|
8.19 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Alterity Therapeutics Limited
ATHE
|
41.4 M | $ 3.9 | 3.7 % | $ 9.38 B |  Australia |
 |
CymaBay Therapeutics
CBAY
|
435 M | - | - | $ 3.45 B | USA |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.63 B | $ 20.4 | -0.87 % | $ 954 M | USA |
 |
Aquestive Therapeutics
AQST
|
160 M | $ 4.18 | 1.21 % | $ 447 M | USA |
 |
Avid Bioservices
CDMO
|
337 M | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
215 M | - | - | $ 1.41 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Arcutis Biotherapeutics
ARQT
|
433 M | $ 24.61 | 5.76 % | $ 3.13 B | USA |
 |
Cabaletta Bio
CABA
|
165 M | $ 3.09 | 0.65 % | $ 310 M | USA |
 |
Aeterna Zentaris
AEZS
|
35.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
Checkmate Pharmaceuticals
CMPI
|
78.8 M | - | - | $ 231 M | USA |
 |
AgeX Therapeutics
AGE
|
6.95 M | - | -10.17 % | $ 12.2 K | USA |
 |
Concert Pharmaceuticals
CNCE
|
165 M | - | - | $ 401 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
589 M | $ 1.49 | 9.56 % | $ 397 M | Britain |
 |
CTI BioPharma Corp.
CTIC
|
126 M | - | - | $ 1.2 B | USA |
 |
AIkido Pharma
AIKI
|
113 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
10 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cyclacel Pharmaceuticals
CYCCP
|
8.18 M | - | -4.36 % | $ 27 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
474 M | - | - | $ 2.18 B | USA |
 |
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
986 M | - | - | $ 2.02 B | USA |
|
Forte Biosciences
FBRX
|
82.8 M | $ 26.27 | 0.38 % | $ 340 M | USA |
 |
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | Germany |
 |
Akari Therapeutics, Plc
AKTX
|
47.9 M | $ 3.88 | 2.11 % | $ 261 B | Britain |
 |
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | USA |